Skip to main content
Clinical Trials/NCT06484478
NCT06484478CompletedNot Applicable

A Real-world Monitoring Project Exploring Day-to-day Physical Activity, Sleep, and Quality of Life in Individuals With Fabry Disease.

Royal Free Hospital NHS Foundation Trust1 site in 1 country100 target enrollmentStarted: November 5, 2024Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
100
Locations
1
Primary Endpoint
Quality of life - via EuroQol five-dimension questionnaire (EQ-5D-5L).

Study Overview

Brief Summary

Despite improvements in Fabry disease care in recent years, many patients still have poor outcomes. In addition to the many physical symptoms that patients can experience, the disease also places individuals at an increased risk of mental health conditions, such as anxiety and depression. Low physical activity levels and increased sedentary time are detrimentally associated with anxiety, depression and quality of life in the general population. Currently, no such research has been conducted in individuals with Fabry disease.

Data will consist of: (1) information from hospital medical records, (2) patient reported outcomes collected via questionnaires, and (3) measurements from a clinical-grade wearable device.

Individuals with Fabry disease aged 18 years or above will be considered for eligibility screening.

Detailed Description

Trial assessments:

Baseline questionnaires

Baseline questionnaires will include the Hospital Anxiety and Depression Scale (HADS) and the EuroQol 5-dimension questionnaire (EQ-5D-5L). This will be administered via Qualtrics.

Thigh-worn device (activPAL)

Participants will attach the activPAL device to their anterior thigh for 8 days and continue their usual daily behaviour throughout the week. This will measure sitting, standing, stepping and sleep time. This device is accompanied by a hard copy daily diary, where participants will be asked to input the time they wake up, they get out of bed, they get into bed, and when they go to sleep.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Cross Sectional

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Diagnosis of Fabry disease documented by genotyping and/or enzymatic analysis.
  • •Resident in the UK.
  • •Aged 18 years and over.
  • •Capable of providing informed consent.
  • •Physically able to stand and ambulate independently.

Exclusion Criteria

  • •A known allergy to any materials in the wearable device.
  • •Not able to have or use a wearable.
  • •Taking part in an interventional study which would preclude real-world data collection.
  • •Unable to communicate in English to a sufficient level to permit engagement in the study.

Arms & Interventions

Adults with Fabry disease

Intervention: Wearable technology monitoring (Other)

Outcomes

Primary Outcomes

Quality of life - via EuroQol five-dimension questionnaire (EQ-5D-5L).

Time Frame: Baseline

Quality of life measured using the self-report EuroQol five-dimension questionnaire (EQ-5D-5L). The questionnaire is comprised of five dimensions which are each divided into five levels of severity i.e. 1 = no problem, 2 = slight problems, 3 = moderate problems, 4 = severe problems, and 5 = unable to/extreme problems. A five-digit health state score is then found by combining the levels of severity for each dimension i.e. 11111 is the best health state and 55555 is the worst health state.

Secondary Outcomes

  • Anxiety(Baseline)
  • Depression(Baseline)

Investigators

Sponsor
Royal Free Hospital NHS Foundation Trust
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials